Crenessity CAH denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for crenessity cah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Crenessity for Congenital Adrenal Hyperplasia as Duplicate Therapy — and Why You Can Appeal

Blue Cross Blue Shield plans may deny Crenessity (tildacerfont), a corticotropin-releasing factor type-1 receptor antagonist approved for congenital adrenal hyperplasia (CAH), on the basis that another agent — typically the glucocorticoid replacement therapy already in the patient's regimen — already addresses the condition. The plan's logic is that the new drug overlaps with an existing covered treatment.

This reasoning mischaracterizes Crenessity's mechanism and clinical role. It works by a distinct pathway from glucocorticoid replacement: rather than replacing the missing hormone, it reduces the ACTH overproduction that drives androgen excess. The FDA approved it specifically as an adjunctive therapy alongside glucocorticoids, not as a replacement for them. A duplicate-therapy denial that ignores this distinction is clinically incorrect and appealable.

## Federal Appeal Rights

• ACA §2719 external review: Non-grandfathered plan members may request independent external review after exhausting internal appeals. The standard request window is approximately four months from the final internal denial notice — verify the exact deadline on your denial letter. Expedited review is available for urgent clinical circumstances.
• ERISA §503: Employer-sponsored plan members are entitled to a full-and-fair review with a written explanation of the specific plan provision and clinical rationale used to classify Crenessity as duplicative.

## Concrete Appeal Steps

1. Obtain BCBS's formulary and coverage policy for Crenessity and for the CAH category, so you can address each stated criterion. 2. Request the prescriber's medical-necessity letter explaining that Crenessity acts through a mechanistically distinct pathway (ACTH suppression) from the glucocorticoid(s) already prescribed, and that both are indicated concurrently per the FDA-approved label. 3. Gather clinical documentation: diagnosis records confirming classic or non-classic CAH, current medication list with dates, lab results showing persistent androgen excess or inadequate disease control on current therapy, and clinical notes documenting severity. 4. File the internal appeal with a criteria-mapping cover sheet within the plan's stated deadline.

## Criteria-Mapping Structure

| Plan's Basis for Denial | Your Rebuttal Documentation | |---|---| | Drug is duplicative of existing therapy | FDA label confirming adjunctive indication and distinct mechanism; prescriber letter | | Same therapeutic class or effect | Prescriber letter distinguishing ACTH-receptor mechanism from glucocorticoid replacement | | No added clinical benefit documented | Chart notes showing uncontrolled androgen markers or clinical disease burden on current therapy |

Review the FDA-approved prescribing information for Crenessity and BCBS's published CAH coverage policy before submitting to ensure your letter addresses each specific stated ground for denial.